MedTrace Logo

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

NCT06208124 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-05-28

No results posted yet for this study

Summary

This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations.

Conditions

Interventions

DRUG

IMM-6-415

Twice daily, oral tablet administered in 21-day cycles until treatment discontinuation criteria are met.

Sponsors & Collaborators

  • Immuneering Corporation

    lead INDUSTRY

Principal Investigators

  • Vinny Hayreh, MD · Immuneering Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-27
Primary Completion
2025-04-30
Completion
2025-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06208124 on ClinicalTrials.gov